Antidiabetic treatment trends in a cohort of elderly people with diabetes: The Cardiovascular Health Study, 1989-1997

Nicholas L. Smith, Susan R. Heckbert, Vera A. Bittner, Peter J. Savage, Joshua I. Barzilay, Adrian S Dobs, Bruce M. Psaty

Research output: Contribution to journalArticle

Abstract

OBJECTIVE - This study characterizes the pharmaceutical treatment of type 2 diabetes from 1989-1990 to 1996-1997 in an elderly cohort. RESEARCH DESIGN AND METHODS - A total of 5,888 adults aged ≥65 years were recruited and attended a baseline clinic visit in 1989-1990 (n = 5,201, original cohort) or 1992-1993 (n = 687, African-American [new] cohort) as participants of the Cardiovascular Health Study. Fasting serum glucose (FSG) was measured at baseline. Medication use was ascertained by drug inventory at all annual clinic visits. Diabetes was defined at baseline as insulin or oral hypoglycemic agent (OHA) use or as having an FSG ≥7.0 mmol/l (126 mg/dl), the current consensus definition of diabetes. RESULTS - A total of 387 (7%) original (FSG = 9.8 mmol/l [177 mg/dl]) and 115 (17%) new (FSG = 10.6 mmol/l [191 mg/dl]) cohort members had pharmacologically treated diabetes at baseline. Among those in the original and in the new cohorts who survived follow-up, respectively, OHA use decreased from 80 to 48% (P <0.001) and from 67 to 50% (P <0.003) and insulin use increased from 20 to 33% (P = 0.001) and from 33 to 37% (P = 0.603). There were 396 (8%) original (FSG = 8.8 mmol/l [159 mg/dl]) and 45 (7%) new (FSG = 10.0 mmol/l [181 mg/dl]) cohort members with diabetes untreated at baseline. Among them, respectively, OHA use reached 38 and 30% and insulin use reached 6 and 16% in 1996-1997. CONCLUSIONS - Diabetes was common in this elderly cohort, and >80% of treated patients with diabetes at baseline were not achieving fasting glucose goals of ≤6.7 mmol/l (120 mg/dl). Many untreated at baseline remained untreated after 7 years of follow-up.

Original languageEnglish (US)
Pages (from-to)736-742
Number of pages7
JournalDiabetes Care
Volume22
Issue number5
DOIs
StatePublished - May 1999

Fingerprint

Hypoglycemic Agents
Fasting
Glucose
Health
Ambulatory Care
Serum
Therapeutics
Pharmaceutical Preparations
African Americans
Type 2 Diabetes Mellitus
Research Design
Insulin
Equipment and Supplies

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Smith, N. L., Heckbert, S. R., Bittner, V. A., Savage, P. J., Barzilay, J. I., Dobs, A. S., & Psaty, B. M. (1999). Antidiabetic treatment trends in a cohort of elderly people with diabetes: The Cardiovascular Health Study, 1989-1997. Diabetes Care, 22(5), 736-742. https://doi.org/10.2337/diacare.22.5.736

Antidiabetic treatment trends in a cohort of elderly people with diabetes : The Cardiovascular Health Study, 1989-1997. / Smith, Nicholas L.; Heckbert, Susan R.; Bittner, Vera A.; Savage, Peter J.; Barzilay, Joshua I.; Dobs, Adrian S; Psaty, Bruce M.

In: Diabetes Care, Vol. 22, No. 5, 05.1999, p. 736-742.

Research output: Contribution to journalArticle

Smith, Nicholas L. ; Heckbert, Susan R. ; Bittner, Vera A. ; Savage, Peter J. ; Barzilay, Joshua I. ; Dobs, Adrian S ; Psaty, Bruce M. / Antidiabetic treatment trends in a cohort of elderly people with diabetes : The Cardiovascular Health Study, 1989-1997. In: Diabetes Care. 1999 ; Vol. 22, No. 5. pp. 736-742.
@article{e5085f8857f442af94bc689b19ed271d,
title = "Antidiabetic treatment trends in a cohort of elderly people with diabetes: The Cardiovascular Health Study, 1989-1997",
abstract = "OBJECTIVE - This study characterizes the pharmaceutical treatment of type 2 diabetes from 1989-1990 to 1996-1997 in an elderly cohort. RESEARCH DESIGN AND METHODS - A total of 5,888 adults aged ≥65 years were recruited and attended a baseline clinic visit in 1989-1990 (n = 5,201, original cohort) or 1992-1993 (n = 687, African-American [new] cohort) as participants of the Cardiovascular Health Study. Fasting serum glucose (FSG) was measured at baseline. Medication use was ascertained by drug inventory at all annual clinic visits. Diabetes was defined at baseline as insulin or oral hypoglycemic agent (OHA) use or as having an FSG ≥7.0 mmol/l (126 mg/dl), the current consensus definition of diabetes. RESULTS - A total of 387 (7{\%}) original (FSG = 9.8 mmol/l [177 mg/dl]) and 115 (17{\%}) new (FSG = 10.6 mmol/l [191 mg/dl]) cohort members had pharmacologically treated diabetes at baseline. Among those in the original and in the new cohorts who survived follow-up, respectively, OHA use decreased from 80 to 48{\%} (P <0.001) and from 67 to 50{\%} (P <0.003) and insulin use increased from 20 to 33{\%} (P = 0.001) and from 33 to 37{\%} (P = 0.603). There were 396 (8{\%}) original (FSG = 8.8 mmol/l [159 mg/dl]) and 45 (7{\%}) new (FSG = 10.0 mmol/l [181 mg/dl]) cohort members with diabetes untreated at baseline. Among them, respectively, OHA use reached 38 and 30{\%} and insulin use reached 6 and 16{\%} in 1996-1997. CONCLUSIONS - Diabetes was common in this elderly cohort, and >80{\%} of treated patients with diabetes at baseline were not achieving fasting glucose goals of ≤6.7 mmol/l (120 mg/dl). Many untreated at baseline remained untreated after 7 years of follow-up.",
author = "Smith, {Nicholas L.} and Heckbert, {Susan R.} and Bittner, {Vera A.} and Savage, {Peter J.} and Barzilay, {Joshua I.} and Dobs, {Adrian S} and Psaty, {Bruce M.}",
year = "1999",
month = "5",
doi = "10.2337/diacare.22.5.736",
language = "English (US)",
volume = "22",
pages = "736--742",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "5",

}

TY - JOUR

T1 - Antidiabetic treatment trends in a cohort of elderly people with diabetes

T2 - The Cardiovascular Health Study, 1989-1997

AU - Smith, Nicholas L.

AU - Heckbert, Susan R.

AU - Bittner, Vera A.

AU - Savage, Peter J.

AU - Barzilay, Joshua I.

AU - Dobs, Adrian S

AU - Psaty, Bruce M.

PY - 1999/5

Y1 - 1999/5

N2 - OBJECTIVE - This study characterizes the pharmaceutical treatment of type 2 diabetes from 1989-1990 to 1996-1997 in an elderly cohort. RESEARCH DESIGN AND METHODS - A total of 5,888 adults aged ≥65 years were recruited and attended a baseline clinic visit in 1989-1990 (n = 5,201, original cohort) or 1992-1993 (n = 687, African-American [new] cohort) as participants of the Cardiovascular Health Study. Fasting serum glucose (FSG) was measured at baseline. Medication use was ascertained by drug inventory at all annual clinic visits. Diabetes was defined at baseline as insulin or oral hypoglycemic agent (OHA) use or as having an FSG ≥7.0 mmol/l (126 mg/dl), the current consensus definition of diabetes. RESULTS - A total of 387 (7%) original (FSG = 9.8 mmol/l [177 mg/dl]) and 115 (17%) new (FSG = 10.6 mmol/l [191 mg/dl]) cohort members had pharmacologically treated diabetes at baseline. Among those in the original and in the new cohorts who survived follow-up, respectively, OHA use decreased from 80 to 48% (P <0.001) and from 67 to 50% (P <0.003) and insulin use increased from 20 to 33% (P = 0.001) and from 33 to 37% (P = 0.603). There were 396 (8%) original (FSG = 8.8 mmol/l [159 mg/dl]) and 45 (7%) new (FSG = 10.0 mmol/l [181 mg/dl]) cohort members with diabetes untreated at baseline. Among them, respectively, OHA use reached 38 and 30% and insulin use reached 6 and 16% in 1996-1997. CONCLUSIONS - Diabetes was common in this elderly cohort, and >80% of treated patients with diabetes at baseline were not achieving fasting glucose goals of ≤6.7 mmol/l (120 mg/dl). Many untreated at baseline remained untreated after 7 years of follow-up.

AB - OBJECTIVE - This study characterizes the pharmaceutical treatment of type 2 diabetes from 1989-1990 to 1996-1997 in an elderly cohort. RESEARCH DESIGN AND METHODS - A total of 5,888 adults aged ≥65 years were recruited and attended a baseline clinic visit in 1989-1990 (n = 5,201, original cohort) or 1992-1993 (n = 687, African-American [new] cohort) as participants of the Cardiovascular Health Study. Fasting serum glucose (FSG) was measured at baseline. Medication use was ascertained by drug inventory at all annual clinic visits. Diabetes was defined at baseline as insulin or oral hypoglycemic agent (OHA) use or as having an FSG ≥7.0 mmol/l (126 mg/dl), the current consensus definition of diabetes. RESULTS - A total of 387 (7%) original (FSG = 9.8 mmol/l [177 mg/dl]) and 115 (17%) new (FSG = 10.6 mmol/l [191 mg/dl]) cohort members had pharmacologically treated diabetes at baseline. Among those in the original and in the new cohorts who survived follow-up, respectively, OHA use decreased from 80 to 48% (P <0.001) and from 67 to 50% (P <0.003) and insulin use increased from 20 to 33% (P = 0.001) and from 33 to 37% (P = 0.603). There were 396 (8%) original (FSG = 8.8 mmol/l [159 mg/dl]) and 45 (7%) new (FSG = 10.0 mmol/l [181 mg/dl]) cohort members with diabetes untreated at baseline. Among them, respectively, OHA use reached 38 and 30% and insulin use reached 6 and 16% in 1996-1997. CONCLUSIONS - Diabetes was common in this elderly cohort, and >80% of treated patients with diabetes at baseline were not achieving fasting glucose goals of ≤6.7 mmol/l (120 mg/dl). Many untreated at baseline remained untreated after 7 years of follow-up.

UR - http://www.scopus.com/inward/record.url?scp=0032954650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032954650&partnerID=8YFLogxK

U2 - 10.2337/diacare.22.5.736

DO - 10.2337/diacare.22.5.736

M3 - Article

C2 - 10332674

AN - SCOPUS:0032954650

VL - 22

SP - 736

EP - 742

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 5

ER -